Total
0
Shares
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Anatara Lifesciences (ANR) has entered an immediate trading halt ahead of a capital raise
  • Anatara develops oral solutions for animals and humans with gastrointestinal issues such as IBS and inflammatory bowel disease
  • At this stage, it is uncertain what the funds will be used for, however, Anatara is preparing for IBS human clinical trial before the end of this year
  • The trial will test Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement which has been shown to reduce gut inflammation, promote mucosal healing and reduce associated pains
  • Additionally, the company announced Non-Executive Director and former interim CEO, Dr Tracie Ramsdale, is retiring by rotation at the upcoming Annual General Meeting
  • Company shares last traded for 20 cents on Friday, October 9

Anatara Lifesciences (ANR) has entered an immediate trading halt ahead of a capital raise announcement.

The company will remain in the trading halt until Wednesday, October 21, unless details of the raise are announced earlier.

Anatara Lifesciences is a specialist life sciences company that develops evidence-based oral solutions for people and animals with gastrointestinal diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease.

While it is uncertain exactly what the funds will be put towards, Anatara is preparing for an IBS human clinical trial that will commence before the end of this year.

The trial will test Anatara’s Gastrointestinal ReProgramming (GaRP) dietary supplement, which has been shown to reduce gut inflammation, promote mucosal healing and reduce associated pains.

Additionally, Anatara hopes to soon form a partnership to commercialise its GaRP product.

Before Anatara entered a trading halt this morning, the company announced Non-Executive Director and former interim CEO, Dr Tracie Ramsdale, is retiring by rotation at the upcoming Annual General Meeting. The director isn’t seeking re-election.

“As a Non-Executive Director, Tracie was a member of Anatara’s audit and risk
management committee and the remuneration and nominations committee,” Chair Sue MacLeman said.

“Anatara thanks Tracie for her valuable contribution since joining the board on August 4, 2014,” Sue added.

Company shares last traded for 20 cents on Friday, October 9.

ANR by the numbers
More From The Market Herald
Kopore Metals (ASX:KMT) - Managing Director, Simon Jackson (right)

" Kopore Metals (ASX:KMT) planning capital raise

Kopore Metals (KMT) has entered into a trading halt ahead of an upcoming capital raise.
Bio Gene Technology (ASX:BGT) - CEO & Managing Director, Richard Jagger

" Bio-Gene Technology (ASX:BGT) halts trade following research agreement

Bio-Gene Technology (BGT) has placed its shares in a trading halt while it plans the details of an upcoming capital raising.
Johns Lyng Group (ASX:JLG) - Managing Director and CEO, Scott Didier

" Johns Lyng Group (ASX:JLG) in back-to-back trading halts

Johns Lyng Group (JLG) has entered consecutive trading halts regarding a ‘material’ transaction and a capital raise.
Environmental Group (ASX:EGL) - Chairwoman, Lynn Richardson

" Environmental Group (ASX:EGL) pauses trading as it plans capital raise

The Environmental Group (EGL) has entered into a trading halt as it plans an upcoming capital raise.